Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Table 7
Univariate and multivariate analysis of predicting factors for OS in LVD.
Factors
Univariate hazard ratio (95% CI)
value
Multivariate hazard ratio (95% CI)
value
Age
<75
1 (reference)
≥75
1.64 (1.15–2.32)
0.006
—
Gleason grade group
<4
1 (reference)
≥4
1.71 (1.04–2.82)
0.034
—
Initial PSA level, ng/ml
<100
1 (reference)
≥100
1.000.68–1.48)
0.995
—
TTN, month
<12
1 (reference)
1 (reference)
≥12
0.30 (0.21–0.44)
<0.0001
0.32 (0.05–1.93)
0.214
Nadir PSA level, ng/ml
<0.2
1 (reference)
1 (reference)
≥0.2
3.37 (2.20–5.17)
<0.0001
1.87 (0.78–4.49)
0.159
3-mon PSARR, %
<97
1
0.108
≥97
1.44 (0.92–2.24)
PSARR, % (month)
<8
1 (reference)
1 (reference)
≥8
3.99 (2.58–6.19)
<0.0001
0.71 (0.12–4.13)
0.703
TFNTC, month
<8
1 (reference)
1 (reference)
≥8
0.28 (0.19–0.40)
<0.0001
1.21 (0.46–3.19)
0.706
PSADT, month
<4
1 (reference)
1 (reference)
≥4
0.19 (0.11–0.32)
<0.0001
0.35 (0.17–0.71)
0.004
TTC, month
<26
1 (reference)
1 (reference)
≥26
0.18 (0.12–0.26)
<0.0001
0.57 (0.20–1.64)
0.298
TTN: time to PSA nadir, 3-mon PSARR: posttreatment 3 months’ PSA reduction rate, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, PSADT: PSA doubling time, and TTC: time from ADT to CRPC.
